Hepatitis B in children

Seminars in Liver Disease

Volumn 23, Issue 1, 2003, Pages 59-68

  Broderick, Annemarie L ^b   Jonas, Maureen M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Division of Gastroenterology   (United States)

Author keywords

Children; Hepatitis B; Infants; Perinatal; Treatment; Vaccination

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PREDNISONE;

ANGER; ANOREXIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD DISEASE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DISEASE COURSE; DISEASE TRANSMISSION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEAR; FEBRILE CONVULSION; FEVER; FLU LIKE SYNDROME; GROWTH DISORDER; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; INJECTION PAIN; IRRITABILITY; LIVER CELL CARCINOMA; MULTIPLE SCLEROSIS; MYALGIA; NEUTROPENIA; PERSONALITY DISORDER; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VACCINATION;

EID: 0344642985     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37585     Document Type: Review

References (62)

1. Anonymous. Achievements in Public Health: hepatitis B vaccination - United States, 1982-2002. MMWR Morb Mortal Wkly Rep 2002;51:549-552
2. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-18
3. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis 2002;185:713-719
4. Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986;18:301-307
5. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796-800
6. Barr D, Hershow R, Furner S, Handler A, Levy P. Assessing prenatal hepatitis B screening in Illinois with an inexpensive study design adaptable to other jurisdictions. Am J Public Health 1999;89:19-24
7. Shiraki K. Toward control of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol 2000;15:E11-E15
8. Lee S-D, Tsai Y-T, Wu T-C, et al. Role of caesarean section in prevention of mother-infant transmission of hepatitis B virus. Lancet 1988;2:833-834
9. Beasley RP, Stevens CE, Shiao IS, Meng HC. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975;2:740-741
10. Pickering L. 2000 Red Book: Report of the Committee of Infectious Disease. Elk Grove Village, IL: American Academy of Pediatrics; 2000:98-101
11. Lok AS. Hepatitis B infection: pathogenesis and management. J Hepatol 2000;32:89-97
12. Chu CM, Liaw YF. Natural history of chronic hepatitis B virus infection: an immunopathological study. J Gastroenterol Hepatol 1997;12:S218-S222
13. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996;97:1655-1665
14. Shiraki K, Yoshihara N, Sakurai M, Eto T, Kawana T. Acute hepatitis B in infants born to carrier mother with the antibody to hepatitis B e antigen. J Pediatr 1980;97:768-770
15. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349-352
16. Cacciola I, Cerenzia G, Pollicino T, et al. Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. J Hepatol 2002;36:426-432
17. Kleinknecht C, Levy M, Peix A, et al. Membranous glomerulonephritis and hepatitis B surface antigen in children. J Pediatr 1979;95:946-952
18. Southwest Pediatric Nephrology Study Group. Hepatitis B surface antigenemia in North American children with membranous glomerulonephropathy. J Pediatr 1985;106:571-578
19. Lok ASF, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988;8:1130-1133
20. Lok ASF, Lai CL, Su PC, et al. Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin Liver Dis 1989;9:249-253
21. Hsu H-Y, Chang M-H, Lee C-Y, et al. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection. Hepatology 1992;15:382-386
22. Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990;99:805-810
23. Chen PJ, Chen DS. Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives. Semin Liver Dis 1999;19:253-262
24. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-768
25. Tanaka T, Miyamoto H, Hino O, et al. Primary hepatocellular carcinoma with hepatitis B virus-DNA-integration in a 4-year-old boy. Hum Pathol 1986;17:202-204
26. Cheah PL, Looi LM, Lin HP, Yap SF. Childhood primary hepatocellular carcinoma and hepatitis B virus infection. Cancer 1990;65:174-176
27. Giacchino R, Navone C, Facco F, et al. HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases. Dig Dis Sci 1991;36:1143-1146
28. Pontisso P, Basso G, Perilongo G, et al. Does hepatitis B virus play a role in primary liver cancer in children of Western countries? Cancer Detect Prev 1991;15:363-368
29. Hsu HC, Wu MZ, Chang MH, Su IJ, Chen DS. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis. J Hepatol 1987;5:260-267
30. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1906-1907
31. Ruiz-Moreno M, Rua MJ, Molina J, et al. Prospective, randomized trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991;13:1035-1039
32. Barbera C, Bortoletti F, Crivellaro C, et al. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 1994;20:287-290
33. Narkewicz MR, Smith D, Silverman A, et al. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J Pediatr 1995;127:815-818
34. Vajro P, Tedesco M, Fontanella A, et al. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J 1996;15:223-231
35. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988-995
36. Lai CL, Lok AS, Lin HJ, et al. Placebo-controlled trial of recombinant alpha2-interferon in Chinese HBsAg-carrier children. Lancet 1987;2:877-880
37. Lai CL, Lin HJ, Lau JN, et al. Effect of recombinant alpha2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991;78:155-163
38. Sokal EM. Viral hepatitis throughout infancy to adulthood. Acta Gastroenterol Belg 1998;61:170-174
39. Giacchino R, Main J, Timitilli A, et al. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. Liver 1995;15:143-148
40. Gurakan F, Kocak N, Ozen H, Yuce A. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection. Pediatr Infect Dis J 2000;19:52-56
41. Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996;23:131-137
42. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-634
43. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-975
44. Kocak N, Gurakan F, Saltik IN, Ozen H, Yuce A. Long term prognosis of interferon nonresponder children with hepatitis B. Am J Gastroenterol 2000;95:1841
45. Ruíz-Moreno M, Fernández P, Leal A, et al. Pilot interferon-β trial in children with chronic hepatitis B who had previously nor responded to interferon-alfa therapy. Pediatrics 1997;99:222-225
46. Ballauff A, Schneider T, Gerner P, et al. Safety and efficacy of interferon retreatment in children with chronic hepatitis B. Eur J Pediatr 1998;157:382-385
47. Iorio R, Pensati P, Botta S, et al. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997;16:984-990
48. Gottrand F, Michaud L, Guimber D, et al. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr 1996;155:1031-1034
49. Comanor L, Minor J, Conjeevaram HS, et al. Impact of chronic hepatitis B and interferon-alfa therapy on growth of children. J Viral Hepat 2001;8:139-147
50. Lai C-L, Chien R-N, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68
51. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263
52. Liaw Y-F, Leung NWY, Chang T-T, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180
53. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-1532
54. Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-1713
55. Dikici B, Bosnak M, Kara IH, et al. Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection. Pediatr Infect Dis J 2001;20:988-992
56. Smith N, Yusuf H, Averhoff F. Surveillance and prevention of hepatitis B virus transmission. Am J Public Health 1999;89:11-13
57. Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology 1999;29:924-927
58. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303:833-841
59. Anonymous. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996;45:1-35
60. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344:327-332
61. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001;344:319-326
62. Giacchino R, Main J, Timitilli A, et al. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. Liver 1995;15:143-148